retatrutide developer eli lilly #elililly #retatrutide #weightloss #obesitycare #glp1 #healthcareinnovation #pharma #biopharma #metabolichealth #pharmanews 🎥 Eli Lilly’s next generation

Similar to the activity of GLP1 cells in the periphery and the CNS (Daniels & MietlickiBaase, 2019), GLP1 receptor expressing neurons in the paraventricular hypothalamic nucleus are activated in response to refeeding (Table 1) (Li, Navarrete, et al., 2019)

95% CI, 0.54-0.98), and DPP-4i (HR, 0.77

GLP-1 users had a 12% lower risk of dementia and a reduced likelihood of psychosis and schizophrenia

Evaluation of antidiabetic, antioxidant and nephroprotective activity of flavonoid rich fraction of Hybanthus enneaspermus in diabetic rats: in-silico molecular docking studies for Sod, catalase, GPX, xanthine oxidase and NF-KB

According to a research article published in February 2024, certain GLP-1 RAs drugs like Semaglutide or Exenatide leverage subcutaneous delivery system to attain peak concentrations more quickly and ensure rapid absorption